表紙
市場調查報告書

慢性淋巴球性白血病(CLL):開發中產品分析

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 192526
出版日期 內容資訊 英文 1353 Pages
訂單完成後即時交付
價格
慢性淋巴球性白血病(CLL):開發中產品分析 Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 1353 Pages
簡介

所謂慢性淋巴球性白血病(CLL)是由骨髓(被稱為淋巴球的)白血球開始發病的癌症之一,之後將侵襲血液。最常見的症狀有異常的瘀傷(缺乏血小板的情況)、發熱、感染疾病的復發、食慾不振或早期飽腹感、體重減少等。治療方法有外科手術、放射線治療、化療,或複數合併療程等。

本報告提供慢性淋巴球性白血病(CLL)的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

慢性淋巴球性白血病(CLL)概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12251IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020, provides an overview of the Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 5, 60, 67, 3, 8, 60, 7 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 10, 16 and 5 molecules, respectively.

Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Chronic Lymphocytic Leukemia (CLL) - Overview
  • Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development
  • Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
  • Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
  • Chronic Lymphocytic Leukemia (CLL) - Drug Profiles
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
  • Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Therapeutics Inc, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acepodia Biotech Inc, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acerta Pharma BV, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics SA, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2020 (Contd..1), H1 2020
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2020 (Contd..2), H1 2020

List of Figures

  • Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020